Across TCGA pan-cancer cohorts, ABHD16A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD16A data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ABHD16A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD16A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, PRAD, and LIHC are the cancer types where ABHD16A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.144	0.604	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.015	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	DFS	Median	II,III,IV	0.718	0.249	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ABHD16A tumor-vs-normal RNA expression · all ABHD16A data types